Aerobika OPEP Device: How It Works and Clinical Evidence

The Aerobika is a handheld oscillating positive expiratory pressure (OPEP) device designed to help people with chronic lung diseases clear mucus from their airways. You breathe out through it, and a mechanical valve inside creates vibrations and back-pressure that loosen secretions stuck in your bronchial tubes, making them easier to cough up. It is most commonly prescribed for people with COPD, bronchiectasis, and cystic fibrosis, though it also shows up in post-surgical recovery settings. The device looks simple enough, but the clinical evidence behind it, the question of how it stacks up against competing devices, and the practical details of using it correctly are all worth unpacking.

How the Aerobika Works

When you exhale through the Aerobika’s mouthpiece, air passes over an internal valve that repeatedly opens and closes. This creates two simultaneous effects: positive expiratory pressure (PEP), which essentially splints your airways open so air can get behind trapped mucus, and oscillation, which sends rapid vibrations through the airway walls to shake mucus loose. The combination is meant to move secretions from deep in the smaller airways up toward the larger airways, where you can cough or huff them out.

The device has a dial that lets you adjust resistance across several settings. At higher resistance, you have to push harder to exhale, which produces greater back-pressure and stronger oscillations. Bench testing has confirmed that increasing the resistance setting on the Aerobika increases both the mean positive expiratory pressure and the peak pressure it delivers, and either maintains or increases the oscillation frequency.¹ In practice, your clinician will typically start you at a lower resistance and increase it as you get comfortable with the device. You can use it in almost any body position, including during postural drainage, which gives it some flexibility over devices that need to be held at a specific angle.²

How It Compares to Other OPEP Devices

The Aerobika is one of several OPEP devices on the market. Others include the Flutter, the Acapella (in several variants), the RC-Cornet, the Pari PEP S, and the Gelomuc. They all work on the same general principle of combining back-pressure with oscillation, but their internal mechanics differ, and bench studies show they do not all behave the same way.

A study testing six OPEP devices during active expiratory flow found that the Flutter, Gelomuc, and Pari devices performed similarly and hit optimal oscillation frequency and PEP values more consistently than the others. The Aerobika, however, produced higher and more consistent oscillation amplitudes when set to medium and high resistance, which suggests it may deliver stronger vibrations in that range.³ A separate bench study comparing four devices (the Aerobika, Acapella, Flutter, and RC-Cornet) confirmed that all fell within their manufacturers’ stated operational parameters when adjusted to low, medium, and high resistance.⁴

The practical takeaway is that the devices are not interchangeable, but no single device has been shown to be clearly superior in clinical outcomes. A Cochrane review of oscillating devices in cystic fibrosis concluded there was no clear evidence that oscillation was more or less effective than other airway clearance techniques overall, and no evidence that one device was superior to another.⁵ The differences show up on bench testing, but clinical trials have not consistently translated those mechanical differences into meaningfully different patient outcomes. This is a recurring theme in airway clearance therapy: the best device tends to be the one you will actually use consistently.

Evidence in COPD

COPD is where the Aerobika has the most clinical data. People with COPD often struggle with mucus retention, which contributes to flare-ups and worsening symptoms over time. The Aerobika is positioned as a tool to reduce that burden.

A functional respiratory imaging study found that using the Aerobika for two weeks led to a small but statistically meaningful increase in specific airway volume of about 3%, suggesting the device helped open up the small airways.⁶ A longer study tracked improvements in airway resistance and lung function out to 24 weeks. Measures of small airway resistance improved significantly at both 12 and 24 weeks, and standard lung function values like forced expiratory volume also improved. Symptom scores on the COPD Assessment Test dropped meaningfully, and exercise capacity measured by a six-minute walk test improved after 24 weeks.⁷

A prospective multicenter study from Québec provides some of the clearest symptom-level data. Among 46 patients using the Aerobika, the average COPD Assessment Test score dropped from about 24 at baseline to about 19 at six weeks and about 16 at twelve weeks. Roughly 70% of patients had reached a clinically meaningful improvement by six weeks, and that number rose to about 85% by twelve weeks.⁸ Another study comparing OPEP therapy to a control group in stable COPD found that the intervention group showed significantly greater improvement in symptom scores and exercise capacity, though quality-of-life improvements were seen in both groups.⁹

These are encouraging numbers, but the studies are mostly small and not all are randomized controlled trials. The direction of the evidence is consistent, though, and COPD guidelines increasingly recognize OPEP therapy as a reasonable adjunct for patients who struggle with mucus clearance.

Evidence in Bronchiectasis and Cystic Fibrosis

Bronchiectasis involves permanently widened airways that trap mucus easily, and regular airway clearance is a central part of managing the condition. A pilot study of patients with bronchiectasis who had frequent flare-ups found that using an OPEP device twice daily increased sputum clearance (the largest volumes were produced around three months in) and significantly improved health questionnaire scores over the treatment period. The researchers noted improvement in symptoms and a reduction in acute exacerbations, without any serious adverse events.¹⁰

In cystic fibrosis, the evidence is broader but the conclusions are surprisingly modest. The Cochrane review mentioned earlier pooled data across multiple oscillating devices and found that while patients often improved compared to their own baseline, there were few differences when comparing oscillating devices to each other or to other airway clearance techniques like chest physiotherapy or autogenic drainage.¹¹ For people with CF, the Aerobika is one valid tool in a larger airway clearance toolkit, and the choice often comes down to patient preference, adherence, and practical considerations like portability.

Technique Matters More Than You Might Expect

One of the less-discussed realities of OPEP devices is that they only work if you use them correctly, and achieving correct technique is harder than it looks. A study specifically examining how children with cystic fibrosis performed with an OPEP device found that none of the participants achieved the target therapeutic pressure ranges during expiration, even after standardized instruction. The pressures they actually generated and the length of their exhalations varied considerably from child to child. The researchers concluded that the airway clearance effects were compromised by poor technique.¹²

This is a sobering finding that applies to adults too, not just kids. The basic instructions seem straightforward: sit upright, take a breath in that is slightly deeper than normal, place the mouthpiece in your mouth forming a seal, and exhale slowly and actively for at least three to four seconds. You should feel the vibrations in your chest, not just in your cheeks. Repeat for a set number of breaths (often 10 to 20), then do a huff cough to move the loosened mucus out. But “slightly deeper than normal” and “slowly and actively” are subjective, and many patients end up breathing too fast, too shallow, or not long enough. If you have been prescribed the Aerobika and are unsure whether you are hitting the right technique, ask your physiotherapist or respiratory therapist to observe you during a session. Visual feedback tools and coaching can make a real difference in whether the device is actually doing its job or just going through the motions.

Combining the Aerobika With Nebulized Medications

One practical advantage of the Aerobika is that it can be paired with a compatible breath-actuated nebulizer, allowing you to inhale your nebulized medication while exhaling through the OPEP device. This combined approach cuts down the total treatment time for people who would otherwise need to do nebulization and airway clearance as separate sessions, which can easily eat up an hour or more of the day.

A study using lung imaging to track drug deposition found that whole lung deposition averaged about 31-32% of the loaded dose whether patients used the nebulizer alone or used it in combination with the Aerobika. In other words, adding the OPEP device to the exhalation path did not significantly reduce how much medication reached the lungs.¹³ For people with conditions like CF or non-tuberculous mycobacterial lung disease, where treatment regimens can involve hypertonic saline nebulization before or during OPEP therapy, this combination approach reduces the daily treatment burden, which matters for long-term adherence.¹⁴

After Surgery

Mucus retention after major surgery, particularly thoracic or abdominal procedures, is a real problem. Patients are often in pain, reluctant to cough, and spending long hours in bed, all of which conspire to let secretions pool in the lungs. The traditional workhorse for this has been the incentive spirometer, the plastic device nurses hand you and tell you to breathe into ten times an hour.

A real-world evidence study compared post-surgical patients who used the Aerobika to those using an incentive spirometer. At 30 days after discharge, the Aerobika group had significantly fewer all-cause rehospitalizations (about 14% versus 23%) and a shorter average length of stay for those who were readmitted. After adjusting for patient characteristics, hospitalization costs were about 80% lower in the Aerobika group.¹⁵ This was not a randomized trial, so the groups may have differed in ways the analysis did not fully capture. Still, the results suggest that actively mobilizing secretions with oscillation and back-pressure may do more for post-surgical patients than the relatively passive breathing exercises an incentive spirometer encourages.

Cleaning the Device

Because you are breathing through the Aerobika and often coughing mucus into or near it, the device can become colonized with bacteria if you do not clean it properly. This is especially concerning for people with CF, where lung infections with organisms like Pseudomonas can be devastating.

A study of airway clearance devices used by CF patients found that before cleaning, the vast majority (28 out of 30 sampled devices) were contaminated. After cleaning, complete eradication of organisms was achieved in half the devices, and partial eradication in another 30%. In a few cases, cleaning was totally ineffective.¹⁶ A separate study examining devices used by children with CF found wide variation in how often patients or caregivers actually cleaned. Only about 42% cleaned after every use, and about a fifth of devices were never cleaned at all. Sterilization methods varied from boiling water to chemical solutions to microwaving in water.¹⁷

The manufacturer’s instructions for the Aerobika typically call for disassembling the device, washing all parts in warm soapy water after each use, rinsing thoroughly, and allowing the parts to air dry on a clean towel. Periodic sterilization by boiling or using a sterilizing solution is also recommended, usually a few times per week. The evidence makes clear that skipping this step is risky, and even following it does not guarantee complete decontamination every time. Keeping up with a cleaning routine and replacing the device at the recommended interval (often every six to twelve months, depending on the manufacturer and your clinical team’s guidance) is a practical necessity rather than optional upkeep.

Cost-Effectiveness and Healthcare Savings

Two economic analyses have modeled the impact of adding the Aerobika to COPD management. One found that the device resulted in cost savings of about $553 per patient per year and about six fewer exacerbations per 100 patients when the effect was conservatively assumed to last only 30 days. When the effect was modeled as lasting longer, cost savings rose to nearly $2,000 per patient and exacerbations dropped by about 21 per 100 patients.¹⁸ A Canadian analysis reached a similar conclusion, estimating about $694 in annual savings per patient along with a small gain in quality-adjusted life years compared to no PEP or OPEP therapy.¹⁹

These models are driven largely by the assumption that fewer exacerbations mean fewer emergency department visits and hospitalizations, which are by far the most expensive events in COPD care. The device itself costs relatively little (typically in the range of $40 to $70 in the U.S., though availability and insurance coverage vary), so even modest reductions in flare-ups can make the math work out. The post-surgical data showing lower rehospitalization costs points in the same direction.²⁰ If you or a family member has been prescribed the Aerobika, it is worth checking whether your insurance covers it, as many respiratory equipment benefit plans do, and hospital discharge programs increasingly include it.

When the Aerobika Is Not Appropriate

OPEP devices in general carry a short list of contraindications. People with untreated pneumothorax (a collapsed lung) should not use any positive expiratory pressure device, because the added pressure could worsen the air leak. Active hemoptysis (coughing up significant amounts of blood) is another standard contraindication, since the oscillation and forced exhalation could aggravate bleeding. People with significant nausea, recent facial or esophageal surgery, or a known ruptured eardrum should also avoid the device or use it only under close supervision. For most people with chronic respiratory disease, though, the device is well tolerated. Even in pediatric patients with asthma in an emergency department setting, the Aerobika did not produce adverse events, though it also did not change asthma severity scores in that particular context.

If you have been handed the device with minimal instruction, the single most impactful thing you can do is get a proper demonstration from a respiratory therapist who can watch your technique and adjust the resistance setting for you. The evidence is clear that owning the device is not the same as using it effectively, and a few minutes of guided practice can be the difference between an expensive paperweight and a genuinely useful tool in your daily routine.